GlassScriptPhysician profile
Danielle Mote
NPI 1205168895
$16,279.13
in general payments reported to CMS, 2019-2025
39 companies · $4,405 in 2025
The $4,405 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,299 · 2022: $2,537 · 2023: $3,412 · 2024: $3,627 · 2025: $4,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,202.58 |
| Education | $241.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,309.41 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,603.34 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $1,616.84 | 2021-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,326.30 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $935.03 | 2021-2025 | Prolastin-C Liquid |
| Electromed, INC. | $800.94 | 2021-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $730.16 | 2022-2025 | Dupixent |
| Genzyme Corporation | $649.54 | 2021-2025 | |
| Amgen INC. | $462.84 | 2022-2025 | Tezspire, Tavneos |
| Actelion Pharmaceuticals US, INC. | $434.97 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Baxter Healthcare | $413.60 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $370.68 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Mylan Specialty L.P. | $356.41 | 2021-2024 | Yupelri |
| Pulmonx Corporation | $239.88 | 2022-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Verona Pharma, INC. | $222.47 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $201.23 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $196.97 | 2021-2024 | Glassia |
| Merck Sharp & Dohme LLC | $156.88 | 2023-2025 | Zerbaxa, Winrevair, Keytruda |
| Viatris Specialty LLC | $153.46 | 2025 | Yupelri |
| Genentech USA, INC. | $146.69 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $136.93 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $110.23 | 2021-2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $93.87 | 2021-2023 | Airduo Digihaler |
| La Jolla Pharmaceutical Company | $80.47 | 2024-2025 | Giapreza |
| Breas Medical, INC. | $74.41 | 2024 | Vivo 45 Ls |
| Advanced Respiratory, INC | $65.74 | 2021 | |
| Ambu INC. | $62.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Csl Behring | $55.11 | 2021 | |
| Inspire Medical Systems, INC. | $39.60 | 2024 | Inspire |
| Inogen, INC. | $35.55 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.39 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.79 | 2022 | |
| Shionogi INC | $18.18 | 2024 | Fetroja |
| Liquidia Technologies, INC. | $18.17 | 2025 | Yutrepia |
| Gilead Sciences, INC. | $16.71 | 2021 | |
| Pfizer INC. | $13.43 | 2021 | |
| Nabriva Therapeutics, Plc | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.